Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of a large drop in short interest in the month of December. As of December 13th, there was short interest totalling 3,400,000 shares, a drop of 6.1% from the November 28th total of 3,620,000 shares. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is presently 3.4 days. Currently, 9.9% of the shares of the stock are sold short.

A number of research analysts have weighed in on the company. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Piper Jaffray Companies restated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 16th. Goldman Sachs Group raised their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Finally, William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company. Crispr Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $71.38.

NASDAQ CRSP opened at $66.01 on Monday. Crispr Therapeutics has a 52 week low of $26.00 and a 52 week high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $64.60 and its 200-day simple moving average is $50.48. The firm has a market cap of $3.64 billion, a PE ratio of -19.19 and a beta of 3.30.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Research analysts expect that Crispr Therapeutics will post 0.65 EPS for the current year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now owns 7,500 shares in the company, valued at approximately $465,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 in the last three months. 21.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. NEXT Financial Group Inc raised its holdings in shares of Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE raised its holdings in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the period. Coastal Investment Advisors Inc. purchased a new position in shares of Crispr Therapeutics during the 3rd quarter worth $26,000. BSW Wealth Partners purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth $39,000. Finally, BNP Paribas Arbitrage SA purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth $41,000. Institutional investors and hedge funds own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: Why do companies engage in swaps?

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link